Welcome to our dedicated page for Cocrystal Pharma news (Ticker: COCP), a resource for investors and traders seeking the latest updates and insights on Cocrystal Pharma stock.
Cocrystal Pharma, Inc. (Nasdaq: COCP) is a clinical-stage biotechnology company developing antiviral therapeutics that target the replication machinery of viruses such as influenza viruses, coronaviruses, noroviruses and hepatitis C viruses. This news page compiles company announcements, press releases and regulatory disclosures so readers can follow Cocrystal’s scientific, clinical and corporate developments over time.
Visitors can review updates on CDI-988, Cocrystal’s oral pan-viral 3CL protease inhibitor being advanced as a potential prevention and treatment for norovirus infections and for coronavirus infections. Recent news has highlighted FDA Investigational New Drug (IND) clearance, a Study May Proceed Letter for a Phase 1b human challenge study, Institutional Review Board approval at Emory University School of Medicine, and previously reported favorable Phase 1 safety and tolerability data.
The feed also covers progress in the company’s influenza programs, including oral and inhaled CC-42344 for pandemic and seasonal influenza A and an influenza A/B polymerase complex program supported by a National Institutes of Health Small Business Innovation Research (SBIR) Phase I award. Articles describe human challenge studies, preclinical findings against highly pathogenic avian influenza strains and external validation through government funding.
In addition to R&D news, this page includes capital markets and corporate updates, such as registered direct offerings, private placements of common stock and warrants, and conference presentations where Cocrystal’s leadership provides company overviews and clinical progress updates. Investors and observers can use this centralized news stream to follow key milestones, including clinical trial initiations, data presentations, grant awards and financing transactions related to COCP.
Cocrystal Pharma (Nasdaq: COCP) will present at the Life Science Innovation Northwest 2022 conference on April 20-21, 2022, at the Washington State Convention Center in Seattle. Sam Lee, PhD, President and co-interim CEO, is set to deliver a presentation during the Neuroscience & Pharmaceuticals segment on April 20 at 3:25 PM Pacific. This conference is the Pacific Northwest’s largest annual life science event, aiming to connect investors, researchers, and organizations to discuss significant life science breakthroughs.
Cocrystal Pharma, Inc. (Nasdaq: COCP) announced that James Martin, Chief Financial Officer and co-interim CEO, will present at the NobleCon18 Investor Conference on April 21, 2022, at 9:30 a.m. ET, held at the Hard Rock Hotel & Casino in Hollywood, Florida. A video webcast of the presentation will be available the next day on the Company's website, as well as on Noble Capital Markets’ and Channelchek's websites, archived for 90 days.
Cocrystal, a clinical-stage biotechnology company, focuses on developing novel antiviral therapeutics targeting various viruses.
Cocrystal Pharma, Inc. (COCP) announced preliminary results from its Phase 1 study of CC-42344, an oral antiviral targeting influenza A. The study, involving 56 healthy participants, demonstrated a favorable safety and pharmacokinetic profile with promising oral bioavailability and dose-dependent plasma exposures. CC-42344 is designed to address pandemic and seasonal influenza strains, aiming to be a best-in-class treatment option. Full results are expected later in 2022, affirming Cocrystal's commitment to advancing antiviral therapies.
Cocrystal Pharma, Inc. (Nasdaq: COCP) has commenced enrollment in a Phase 1 trial for CC-42344, an orally administered antiviral for influenza A. The company plans to initiate two additional Phase 1 trials in 2022 for COVID-19 antiviral candidates. Notably, Cocrystal reported no revenues for 2021, down from $2 million in 2020, and a net loss of $14.2 million, or $0.16 per share. However, cash reserves increased to $58.7 million, up from $33 million year-over-year, providing sufficient funds for operations through 2023.
Cocrystal Pharma, Inc. (Nasdaq: COCP) will participate in the 2022 Virtual Growth Conference hosted by Maxim Group and M-Vest from March 28-30, 2022. Interested attendees can register online. A pre-recorded presentation will be accessible for 72 hours starting March 28 at 9:00 a.m. ET. Cocrystal Pharma is focused on developing antiviral therapeutics targeting influenza, coronaviruses, hepatitis C, and noroviruses, utilizing advanced technologies and expertise.
Cocrystal Pharma has initiated dosing in a Phase 1 clinical trial for its antiviral drug CC-42344, targeting both pandemic and seasonal influenza A. Conducted in Australia, this study will assess the drug's safety and pharmacokinetics in 56 healthy adults. CC-42344 is designed to inhibit influenza viral replication and potentially act against drug-resistant strains. Results are expected later this year, marking a key step in Cocrystal's development of innovative antiviral therapies.
Cocrystal Pharma (Nasdaq: COCP) announces participation in two investment conferences. The Q1 Investor Summit on March 8-9 will feature a presentation on March 9 at 11:45 a.m. Eastern time. Additionally, the company will attend the 34th Annual Roth Conference from March 13-15 in California. Cocrystal plans to start enrollment for a Phase 1 trial of influenza A and initiate studies on two SARS-CoV-2 antivirals for COVID-19 treatments. The company emphasizes its strong financial position to support these developments.
Cocrystal Pharma (Nasdaq: COCP) announced the selection of two investigational oral antiviral candidates, CDI-988 and CDI-873, for the treatment of SARS-CoV-2, showing superior in vitro potency against the virus and its variants, including Omicron.
Both candidates are poised for first-in-human trials in 2022, leveraging Cocrystal's proprietary drug discovery platform. The company also plans to expedite the development of an inhalation candidate, CDI-45205. Positive preclinical results and FDA guidance for CDI-45205 support upcoming clinical study plans.
Cocrystal Pharma (Nasdaq: COCP) announced receiving FDA guidance for the development of CDI-45205, a novel SARS-CoV-2 protease inhibitor, as a potential COVID-19 treatment. The FDA's response, which followed a pre-IND briefing, provides insights necessary for advancing the clinical development, including plans for a Phase 1 study set to begin in 2022. Cocrystal aims to conduct formulation development and IND-enabling studies, emphasizing the compound's antiviral efficacy against various SARS-CoV-2 variants, including Omicron.
Cocrystal Pharma (Nasdaq: COCP) announced its participation in the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. A webcast of the presentation will be available on January 10, 2022, at 7:00 a.m. ET. The company aims to initiate first-in-human studies for two SARS-CoV-2 antivirals targeting COVID-19 and is progressing with its influenza A Phase 1 trial. Cocrystal is well positioned financially with a solid cash position and a debt-free balance sheet, allowing it to advance its clinical plans.